No abstract

to 11%-16% of ezetimibe users, and 11%-19% of fibrate users. Nearly 4% of statin users augmented their regimen during the year, compared with 56%-61% of ezetimibe and 38%-51% of fibrate users. The proportion of patients not meeting the LDL-C target was 71% and 69% in the CV High Risk and CV Event History cohorts at index, respectively, and 65% for both at 12 months. Approximately 60% of diabetic patients of CV High Risk cohort did not meet LDL-C target at both index and 12 months. ConClusions: Adherence to LMT after CV events was best for statins. Patients receiving fibrates or ezetimibe had higher rates of switching or augmentation. LDL-C goal attainment is low, representing a substantial unmet medical need.

No abstract

No abstract

No abstract